Expression of Fhit, hWAPL and Survivin in Cervical Squamous Cell Carcinoma and Significance Thereof
Science Journal of Public Health
Volume 8, Issue 4, July 2020, Pages: 108-114
Received: Jun. 28, 2020; Published: Jun. 29, 2020
Views 14      Downloads 39
Authors
Yongmei Li, Department of Gynecology, Binzhou People's Hospital, Binzhou, P. R. China
Yubin Zhang, Department of Nuclear Medicine, Binzhou People's Hospital, Binzhou, P. R. China
Lin Li, Department of Gynecology, Binzhou People's Hospital, Binzhou, P. R. China
Article Tools
Follow on us
Abstract
Objective To preliminarily discuss the role of fragile histidine triad (FHIT) gene, human wings apart-like (hWAPL) gene, survivin gene in lymphatic metastasis of cervical squamous cell carcinoma. Method Expression of FHIT, hWAPL and survivin in 30 cases of normal squamous epithelium, 30 cases of CIN III and 60 cases of cervical squamous cell carcinoma was detected using the immunohistochemical technique. A statistical analysis was conducted for the relationship between the expression levels of FHIT, hWAPL and survivin and clinical pathologic parameters through expression count LVD of FHIT. Results FHIT value is 1.93±0.57 in the group of normal squamous epithelium, 2.87±0.63 in the group of CIN III and 4.12±0.72 in the group of cervical squamous cell carcinoma. The difference has statistical significance (P<0.05). The positive expression of hWAPL in normal cervical tissues is 0.00% (0/30), the positive expression rate is 36.67% (11/30) in the group of CIN III, and the positive expression rate is 63.33% (38/60) in the group of cervical squamous cell carcinoma. The difference has statistical significance (P<0.01). The positive expression rate of survivin in normal cervical tissues is 0.00% (0/30), the positive expression rate is 30.00% (9/30) in the group of CIN III, the expression rate is 61.67% (37/60) in the group of cervical squamous cell carcinoma. The difference has statistical significance (P<0.01). Conclusion FHIT, hWAPL and survivin promote lymphangiogenesis during occurrence and progression of cervical squamous cell carcinoma and lymphangiogenesis plays a vital role in lymphatic metastasis of cervical squamous cell carcinoma.
Keywords
FHIT, hWAPL, Survivin, Cervical Squamous Cell Carcinoma, Lymphatic Vessels
To cite this article
Yongmei Li, Yubin Zhang, Lin Li, Expression of Fhit, hWAPL and Survivin in Cervical Squamous Cell Carcinoma and Significance Thereof, Science Journal of Public Health. Vol. 8, No. 4, 2020, pp. 108-114. doi: 10.11648/j.sjph.20200804.13
References
[1]
Yang W. Kim Y. et al. Rotating-shield brachytherapy for cervical cancer [J]. Phys Med Biol, 2019, 58 (11): 3931-41.
[2]
Sogukpinar N. Saydam BK. et al. Assessment of Cervical Cancer Risk in Women between 15 and 49 Years of Age: Case of Izmir [J]. Asian Pac J Cancer Prev, 2019, 14 (3): 2119-25.
[3]
Pesee M. Kirdpon W. et al. Palliative treatment of advanced cervical cancer with radiotherapy and thai herbal medicine as supportive remedy - analysis of survival [J]. Asian Pac J Cancer Prev, 2013, 14 (3): 1593-6.
[4]
Speiser D. Kohler C. et al. Radical vaginal trachelectomy: a fertility-preserving procedure in early cervical cancer in young women [J]. Dtsch Arztebl Int, 2019, 110 (17): 289-95.
[5]
Maver PJ. Seme K. et al. Cervical cancer screening practices in central and eastern Europe in 2012 [J]. Acta Dermatovenerol Alp Panonica Adriat, 2013, 22 (1): 7-19.
[6]
Bhaumik S. India has world's highest number of cervical cancer deaths [J]. BMJ, 2013, 346 (17): 3108-10.
[7]
Sicam RV. Huang KG. et al. Maintenance of ovarian function in end-of-life cervical cancer patient following primary surgico-radiotherapy and ovarian transposition [J]. J Gynecol Oncol, 2013, 24 (2): 204-7.
[8]
Ushijima K. Fujiyoshi K. et al. Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study [J]. J Gynecol Oncol, 2019, 24 (2): 108-13.
[9]
Bai H. Ge S. et al. Hypoxia inducible factor-1alpha-mediated activation of survivin in cervical cancer cells [J]. J Obstet Gynaecol Res, 2019, 39 (2): 555-63.
[10]
Kasuya G. Ogawa K. et al. Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival [J]. Anticancer Res, 2013, 33 (5): 2199-204.
[11]
Shen SN. Wang LF. et al. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer [J]. Diagn Pathol, 2019, 8 (1): 69-72.
[12]
Poliquin V. Decker K. et al. Changes in cervical cancer screening behavior for women attending Pap Test Week clinics [J]. Int J Womens Health, 2019, 5 (1): 141-8.
[13]
Kai-Jiang L. Xin-Wei L. et al. Application of carbon nanoparticles in the laparoscopic sentinel lymph node detection in patients with cervical cancer [J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2019, 35 (2): 150-4.
[14]
Biedka M. Makarewicz R. et al. Labeling of microvessel density, lymphatic vessel density and potential role of proangiogenic and lymphangiogenic factors as a predictive/prognostic factors after radiotherapy in patients with cervical cancer [J]. Eur J Gynaecol Oncol, 2019, 33 (4): 399-405.
[15]
Xiong Y. Cao LP. et al. Clinical significance of peritumoral lymphatic vessel density and lymphatic vessel invasion detected by D2-40 immunostaining in FIGO Ib1-IIa squamous cell cervical cancer [J]. Cell Tissue Res, 2019, 348 (3): 515-22.
[16]
Lee TS. Kang SB. et al. Chemoradiation with Paclitaxel and Carboplatin in high-risk cervical cancer patients after radical hysterectomy: a korean gynecologic oncology group study [J]. Int J Radiat Oncol Biol Phys, 2019, 86 (2): 304-10.
[17]
Balsat C. Blacher S. et al. Whole slide quantification of stromal lymphatic vessel distribution and peritumoral lymphatic vessel density in early invasive cervical cancer: a method description [J]. ISRN Obstet Gynecol, 2019, 35 (5): 861-3.
[18]
Cao CX. Ma J. et al. Immunization of mice with plasmids coexpressing HPV16 E5 and the novel oncogene hWAPL [J]. Int J Gynecol Cancer, 2019, 18 (3): 534-9.
[19]
Cao LX. Shen ZF. et al. Research progress about Wapl gene [J]. Sheng Li Ke Xue Jin Zhan, 2010, 4 (1): 27-30.
[20]
Puranik AD. Purandare NC. et al. Isolated mandibular condylar metastases: An uncommon manifestation of recurrent cervical cancer [J]. J Cancer Res Ther, 2019, 9 (1): 108-10.
[21]
Gao Y. Gao F. et al. Treatment results of incomplete chemoradiotherapy in locally advanced cervical cancer [J]. Onco Targets Ther, 2013, 6 (1): 297-302.
[22]
Oikawa K. Akiyoshi A. et al. Expression of various types of alternatively spliced WAPL transcripts in human cervical epithelia [J]. Gene, 2018, 423 (1): 57-62.
[23]
Alsbeih G. Al-Harbi N. et al. HPV prevalence and genetic predisposition to cervical cancer in Saudi Arabia [J]. Infect Agent Cancer, 2019, 8 (1): 15-7.
[24]
Laudadio J. Human papillomavirus detection: testing methodologies and their clinical utility in cervical cancer screening [J]. Adv Anat Pathol, 2018, 20 (3): 158-67.
[25]
Jeong BK. Huh SJ. et al. Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer [J]. Cancer Res Treat, 2018, 45 (1): 48-54.
[26]
Chen ZY. Liang K. et al. Study of the UTMD-Based Delivery System to Induce Cervical Cancer Cell Apoptosis and Inhibit Proliferation with shRNA targeting Survivin [J]. Int J Mol Sci, 2019, 14 (1): 1763-77.
[27]
Huang Z. Mayr NA. et al. Characterizing at-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer during Radiotherapy [J]. J Cancer Sci Ther, 2018, 4 (9): 254-259.
[28]
Lu D. Qian J. et al. Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation [J]. Br J Biomed, 2020, 69 (4): 143-6.
[29]
Wu SF. Zhang JW. et al. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis [J]. Eur Rev Med Pharmacol, 2018, 16 (15): 2044-50.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186